A2 Bio Stock
HealthTechLooking to sell A2 Bio stock or options?
A2 Bio is the developer of a cell therapy aimed at curing cancer through precise tumor targeting. The company creates engineered tumor cells that focus on the genetic material deficiencies in tumors, selectively destroying tumor cells while sparing normal ones. This innovative approach allows physicians to transform the treatment of solid tumors.
Investors Include:
BCM Ventures, Casdin Capital, S32, Hartford Healthcare Endowment, Mana Ventures, C/O Uc San Francisco, Samsara BioCapital, Euclidean Capital, Merck & Co., Vida Ventures (Boston), UC Investments, StepStone Group, Schroders, The Column Group, Nextech Invest.